Navigation Links
Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
Date:1/31/2012

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), has released upgrades to its electronic data capture system SynCapture™, providing customers with increased user functionality. SynCapture allows for clinical study data to be captured into a single database using multiple modes of entry including paper, fax, and web based, resulting in more seamless, flexible and cost effective data capture.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

"We understand that low cost EDC is critical, especially in smaller trials," said Wendel Barr, chief executive officer at Synteract. "SynCapture has been an effective solution to handle the needs of our clients since it was first implemented in 2005.  SynCapture 1.5 integrates features that enhance our cost efficient EDC offering, so we can continue to meet each client's unique program requirements."

SynCapture 1.5 provides users the ability to re-query investigative sites on data collected, an upgrade sponsors requested. In addition, the new release brings enhanced audit trail legibility and functionality useful to all project team members, as well as features that increase the ease and efficiency of the query resolution process.

"SynCapture 1.5 provides users increased functionality and easier data collection," said Olivia Montano, senior director of clinical data management at Synteract. "The main reason for the upgrade was to improve the user experience.  We took into account direct requests from users, since customer service is so integral to what we do at Synteract. This SynCapture upgrade allows us to provide clients an improved option for on-time delivery of quality data to help them get to decision points faster."

About Synteract, Inc.

Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.

CONTACT:

Rachel Hutman
Clearpoint Agency, for Synteract
rachel@clearpointagency.com
760-230-2424

 


'/>"/>
SOURCE Synteract, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):